Synagistics Limited — Board/Management Information 2022

Mar 14, 2022

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [63 x 86] intentionally omitted <==

WEALTHKING INVESTMENTS LIMITED 華 科 資 本 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)

CHANGE OF CHIEF EXECUTIVE OFFICER

The board (the ‘‘Board’’ ) of directors of Wealthking Investments Limited (the ‘‘Company’’) announces that effective 14 March 2022, Dr. Liu Zhiwei will cease to be the chief executive officer of the Company in order to comply with the code provision C.2.1 of the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange (‘‘Listing Rules’’) that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual.

The Board also announces that Dr. Qiao Bingya will be appointed as the chief executive officer of the Company effective 14 March 2022.

Dr. Qiao, aged 51, has years of experiences in securities regulation and inspection. Prior to joining the Company, Dr. Qiao held a number of senior management positions at the China Securities Regulatory Commission from year 1998 to year 2012 and he also served as an assistant executive president and a member of the executive committee at Bank of China Investment Management Co., Ltd from year 2012 to year 2016. From June 2019 to September 2021, Dr. Qiao served as an executive director of Renaissance Asia Silk Road Group Limited (formerly China Billion Resources Limited), a company listed on the Stock Exchange.

Dr. Qiao obtained a Bachelor degree in Economics from Renmin University of China in 1993, a Master degree in Economics from Graduate School of the Financial Research Institute of the People’s Bank of China in 1996 and a Doctor of Philosophy in Economics from Renmin University of China in 2001.

Currently, Dr. Qiao also serves as the director of a subsidiary of the Company.

– 1 –

The Company has entered into a service contract with Dr. Qiao pursuant to which the term of appointment of Dr. Qiao shall be 3 years which may be terminated by one month’s prior notice in writing served by either party on the other. Dr. Qiao will receive a salary of HK$250,000 per annum pursuant to the service contract entered into between the Company and Dr. Qiao in relation to his appointment as the chief executive office of the Company. The remuneration of Dr. Qiao was determined by the Board with reference to his duties and responsibilities within the Company, and by reference to the prevailing market conditions of companies of comparable size and similar operations. There is no additional remuneration payable to Dr. Qiao for acting as the director of a subsidiary of the Company.

Save as disclosed above, Dr. Qiao (i) does not have any relationship with any director, senior management, substantial or controlling shareholder (having the meaning ascribed to it in the Listing Rules) of the Company; (ii) does not hold any other positions in the Company or its subsidiaries; and (iii) did not hold any directorship in the past three years in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance, Dr. Qiao does not have any interests in the shares of the Company.

ROLES AND RESPONSIBILITIES OF THE CHIEF EXECUTIVE OFFICER

• . Creating the organization and managing the day-to-day operation.

• . Overseeing the day-to-day running in accordance with the business plans and within the budgets approved by the Board.

• . Organizing the implementation of the strategies and policies as approved by the Board and its committees.

• . Ensuring that the board is alerted to sensitive or risk issues affecting the Company.

• . Evaluating the work of other senior management persons.

• . Ensuring the Company maintains high social responsibility.

• . Communicating, on behalf of the Company, with stakeholders and the public.

• . Promoting the highest standards of integrity, probity and corporate governance.

Other than the above, there is no other matter in relation to the appointment of Dr. Qiao as the chief executive officer that needs to be brought to the attention of the shareholders of the Company, nor is there any information that should be disclosed pursuant to any of the requirements of Rule 13.51(2) of the Listing Rules.

– 2 –

The Board would like to express its gratitude to Dr. Liu for his contribution to the Company during his tenure of services as the chief executive officer of the Company, and welcome Dr. Qiao for joining the Company.

By order of the Board Wealthking Investments Limited Liu Zhiwei Executive Director and Chairman

Hong Kong, 14 March 2022

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; two non-executive Directors, namely Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Professor He Jia, Mr. Wang Xiaojun and Mr. Chen Yuming.

– 3 –